Listed below are six key laboratory tests/areas that have an important role in monitoring patients with COVID-19 with specific tests/scores highlighted in [Table 1](#t0005){ref-type="table"} . Additional resources for laboratory related testing may be found at the International Federation of Clinical Chemistry and Laboratory Medicine website (IFCC Information Guide on COVID-19: [https://www.ifcc.org/ifcc-news/2020--03-26-ifcc-information-guide-on-covid-19/](https://www.ifcc.org/ifcc-news/2020%e2%80%9303-26-ifcc-information-guide-on-covid-19/){#ir005}).1.**Complete blood count (CBC) with differential**The three CBC findings of poor prognosis are: leukocytosis, thrombocytopenia, and lymphocytopenia [@b0005], [@b0010], [@b0015]. Lymphocytopenia occurs across populations regardless of co-infection. Whether poor prognosis is associated with lymphocytopenia below the reference interval or absolute count is unclear.2.**Acute phase response and inflammatory biomarkers**COVID-19 patients have high concentrations of the acute phase response proteins (i.e., c-reactive protein \[CRP\] and ferritin) and inflammatory biomarkers (i.e., cytokines such as Interleukin-6; IL-6) at admission [@b0005], [@b0010]. CRP is more widely available, and is a sensitive biomarker of inflammation and tissue damage that is increased at admission and during hospitalization [@b0010], [@b0020].3.**Kidney, liver and cardiac injury**Kidney injury prevalence (via creatinine measurement) at admission is unknown but 11--15% of hospitalized COVID-19 patients may have acute kidney injury [@b0005], [@b0010]. Alanine aminotransferase (ALT) elevations at admission range from 22% to 32% and cardiac injury (via cardiac troponin measurement) has been reported to range from 15% to 44% [@b0005], [@b0010], [@b0015]. Other liver biomarkers are reported to be increased; however, ALT is more specific for liver injury and is also less affected by pre-analytical factors such as hemolysis.4.**Tests which may indicate improvement**Following recovery and 7-days post-convalescent plasma transfusion, CRP levels decreased by \>10-fold, which was more pronounced than IL-6 and procalcitonin (\~2-fold difference) [@b0020]. Procalcitonin is a useful indicator for bacterial infections, though not all patients with COVID-19 have bacterial co-infections [@b0015], [@b0020].5.**Prognostic biomarkers**D-dimer and high-sensitivity cardiac troponin can also identify COVID-19 patients who are at low- and high-risk for death [@b0005], [@b0010], [@b0025]. D-dimer is used in decision making for disseminated intravascular coagulation, deep vein thrombosis or pulmonary embolism and is given a high priority of testing in patients with COVID-19 [@b0025]. While for high-sensitivity cardiac troponin, normal or low concentrations (typically below 5 ng/L, but cutoffs are assay specific) identifies patients at low-risk for cardiovascular outcomes and death in many different populations, including COVID-19 patients [@b0005], [@b0010].6.**Clinical scores**Two clinical scores that may also identify patients with COVID-19 at low- and high-risk for death are the sequential organ failure assessment (SOFA) score used in sepsis and the confusion, urea, respiratory rate, blood pressure, and age ≥65 years (CURB-65) score in the assessment of severity in patients with community acquired pneumonia. Both clinical scores require laboratory testing. Table 1Emerging key laboratory tests for patients with COVID-19.Laboratory TestRole in COVID-19Lymphocyte count•At least 75% of patients have a count \<1.5 × 10^9^/L [@b0005], [@b0010], [@b0015].•Patients with persistently low counts during hospitalization have a poor prognosis [@b0005].C-reactive protein (CRP)•CRP median concentrations differ between non-survivors (n = 113) versus survivors (n = 161) (113 mg/L vs. 26 mg/L) as does ferritin (1418 µg/L vs. 481 mg/L) and IL-6 (72 ng/L vs. 13 ng/L) [@b0010].•Before convalescent plasma transfusion the median CRP concentration in 5 COVID-19 patients was 163 mg/L and at 12-days post-transfusion with no virus detected the median CRP concentration was 6 mg/L [@b0020]. Of note, CRP concentrations \<10 mg/L typically indicate no appreciable acute phase response.Alanine Aminotransferase (ALT)•Using an overall cutoff of \>40 U/L approximately 30% of COVID-19 patients had liver injury at admission [@b0005], [@b0015].•The rate of liver injury could be higher in females as the upper limit of normal is typically lower in females as compared to males.D-dimer•At admission 50% of patients who survived had concentrations \<0.6 µg/mL while the non-survivors at least 75% had concentrations \>1.3 µg/mL [@b0005], [@b0010].High-sensitivity cardiac troponin•At admission, 50% of the survivors had a high-sensitivity cardiac troponin I concentration ≤3 ng/L (a low normal level) [@b0005], [@b0010].Clinical Scores•Creatinine, total bilirubin, pO~2~ and platelet count are used for the SOFA (sequential organ failure assessment) score; while urea is used for the CURB-65 (confusion, urea, respiratory rate, blood pressure and age ≥65 years) score [@b0005]. Lactate levels are also used to identify septic shock.
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